News and Announcements
MD Anderson Leukaemia Expert Joins Prescient Therapeutics SAB
- Published November 27, 2015 3:34PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
26th November 2015, ASX Announcement
Cancer drug development company Prescient Therapeutics Ltd (ASX: PTX) is delighted to announce the appointment of an internationally regarded leukemia authority to its Scientific Advisory Board.
Professor Farhad Ravandi MD is based at the MD Anderson and Moffitt Cancer Center, which is one of the world’s most prestigious cancer institutions.
He currently holds position as Professor and Chief, Section of Developmental Therapeutics within the Department of Leukemia (AML) in early 2016.
Professor Ravandi is actively involved in clinical and translational research for the treatment of patients with various hematological malignancies, with a particular focus on leukemias.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
